265 related articles for article (PubMed ID: 29881922)
21. High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of
Stroot IAS; Brouwer J; Bart J; Hollema H; Stommel-Jenner DJ; Wagner MM; van Doorn HC; de Hullu JA; Gaarenstroom KN; Beurden M; van Lonkhuijzen LRCW; Slangen BFM; Zweemer RP; Gómez Garcia EB; Ausems MGEM; Boere IA; van Engelen K; van Asperen CJ; Schmidt MK; Wevers MR; de Bock GH; Mourits MJE;
J Clin Oncol; 2023 May; 41(14):2523-2535. PubMed ID: 36809028
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
[TBL] [Abstract][Full Text] [Related]
23. What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy.
Hickey M; Moss KM; Krejany EO; Wrede CD; Domchek SM; Kirk J; Brand A; Trainer A; Mishra GD; Baker FC
Gynecol Oncol; 2021 Aug; 162(2):447-453. PubMed ID: 34116835
[TBL] [Abstract][Full Text] [Related]
24. Changes in Bone Density in Carriers of BRCA1 and BRCA2 Pathogenic Variants After Salpingo-Oophorectomy.
Chan LN; Chen LM; Goldman M; Mak JS; Bauer DC; Boscardin J; Schembri M; Bae-Jump V; Friedman S; Jacoby VL
Obstet Gynecol; 2023 Jul; 142(1):160-169. PubMed ID: 37290104
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P;
Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637
[TBL] [Abstract][Full Text] [Related]
26. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA
BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255
[TBL] [Abstract][Full Text] [Related]
27. Study on the psychosocial aspects of risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers in Japan: a preliminary report.
Shigehiro M; Kita M; Takeuchi S; Ashihara Y; Arai M; Okamura H
Jpn J Clin Oncol; 2016 Mar; 46(3):254-9. PubMed ID: 26685323
[TBL] [Abstract][Full Text] [Related]
28. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
Domchek SM; Friebel TM; Garber JE; Isaacs C; Matloff E; Eeles R; Evans DG; Rubinstein W; Singer CF; Rubin S; Lynch HT; Daly MB; Weitzel J; Ganz PA; Pichert G; Olopade OI; Tomlinson G; Tung N; Blum JL; Couch F; Rebbeck TR
Breast Cancer Res Treat; 2010 Nov; 124(1):195-203. PubMed ID: 20180014
[TBL] [Abstract][Full Text] [Related]
29. Urinary incontinence more than 15 years after premenopausal risk-reducing salpingo-oophorectomy: a multicentre cross-sectional study.
Terra L; Heemskerk-Gerritsen BAM; Beekman MJ; Engelhardt E; Mourits MJE; van Doorn HC; de Hullu JA; Mom CH; Slangen BFM; Gaarenstroom KN; van Beurden M; Roeters Van Lennep JE; van Dorst EBL; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; Steensma AB; van Leeuwen FE
BJOG; 2024 Jan; 131(1):99-108. PubMed ID: 37394722
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
[TBL] [Abstract][Full Text] [Related]
31. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
Chai X; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Tung N; Weitzel JN; Couch FJ; Hulick PJ; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Blum JL; Domchek SM; Chen J; Rebbeck TR
Breast Cancer Res Treat; 2014 Nov; 148(2):397-406. PubMed ID: 25311111
[TBL] [Abstract][Full Text] [Related]
32. The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause.
Pezaro C; James P; McKinley J; Shanahan M; Young MA; Mitchell G
Fam Cancer; 2012 Sep; 11(3):403-10. PubMed ID: 22477030
[TBL] [Abstract][Full Text] [Related]
33. Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience.
Harmsen MG; Arts-de Jong M; Horstik K; Manders P; Massuger LFAG; Hermens RPMG; Hoogerbrugge N; Woldringh GH; de Hullu JA
Gynecol Oncol; 2016 Oct; 143(1):113-119. PubMed ID: 27430397
[TBL] [Abstract][Full Text] [Related]
34. Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer.
Michelsen TM; Dørum A; Tropé CG; Fosså SD; Dahl AA
Int J Gynecol Cancer; 2009 Aug; 19(6):1029-36. PubMed ID: 19820364
[TBL] [Abstract][Full Text] [Related]
35. No signs of subclinical atherosclerosis after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.
van Bommel MHD; de Jong MA; Steenbeek MP; Bots ML; van Westerop LLM; Hopman MTE; Hoogerbrugge N; de Hullu JA; Maas AHEM
J Cardiol; 2021 Jun; 77(6):570-575. PubMed ID: 33229237
[TBL] [Abstract][Full Text] [Related]
36. Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation.
Kim D; Kang E; Hwang E; Sun Y; Hwang Y; Yom CK; Kim K; No JH; Kim YB; Kim SW
Fam Cancer; 2013 Dec; 12(4):621-8. PubMed ID: 23504064
[TBL] [Abstract][Full Text] [Related]
37. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM
Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636
[TBL] [Abstract][Full Text] [Related]
38. Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines.
Vermeulen RFM; Korse CM; Kenter GG; Brood-van Zanten MMA; Beurden MV
Climacteric; 2019 Aug; 22(4):352-360. PubMed ID: 30905183
[No Abstract] [Full Text] [Related]
39. Setting the Threshold for Surgical Prevention in Women at Increased Risk of Ovarian Cancer.
Manchanda R; Menon U
Int J Gynecol Cancer; 2018 Jan; 28(1):34-42. PubMed ID: 29252925
[TBL] [Abstract][Full Text] [Related]
40. Surgical decision making in premenopausal
Gaba F; Goyal S; Marks D; Chandrasekaran D; Evans O; Robbani S; Tyson C; Legood R; Saridogan E; McCluggage WG; Hanson H; Singh N; Evans DG; Menon U; Manchanda R;
J Med Genet; 2022 Feb; 59(2):122-132. PubMed ID: 33568437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
